A CIBMTR registry cohort (n=10,025) found donor age predicted worse overall survival with conventional calcineurin inhibitor prophylaxis but not with posttransplant cyclophosphamide (PTCy); attenuation was driven by reduced nonrelapse mortality in PTCy recipients.